{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:59:38Z","timestamp":1787759978580,"version":"build-2784847793"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40271-021-00525-z","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T02:02:41Z","timestamp":1623808961000},"page":"93-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Patient Perspectives and Experiences of Preventive Treatments and Self-Injectable Devices for Migraine: A Focus Group Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6061-4301","authenticated-orcid":false,"given":"Jaein","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommi","family":"Tervonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Hareendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet H.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia L.","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Harrison","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Tockhorn-Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"issue":"11","key":"525_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"Collaborators GBDH","year":"2018","unstructured":"Collaborators GBDH. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954\u201376.","journal-title":"Lancet Neurol."},{"issue":"1","key":"525_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1526-4610.1993.hed3301029.x","volume":"33","author":"PE Stang","year":"1993","unstructured":"Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache. 1993;33(1):29\u201335.","journal-title":"Headache"},{"issue":"11","key":"525_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"Group GBDNDC","year":"2017","unstructured":"Group GBDNDC. Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877\u201397.","journal-title":"Lancet Neurol."},{"issue":"1","key":"525_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","volume":"16","author":"Z Katsarava","year":"2012","unstructured":"Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86\u201392.","journal-title":"Curr Pain Headache Rep."},{"issue":"6","key":"525_CR5","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1468-2982.2006.01172.x","volume":"26","author":"J Olesen","year":"2006","unstructured":"Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26(6):742\u20136.","journal-title":"Cephalalgia"},{"key":"525_CR6","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"5","key":"525_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/0333102415604471","volume":"36","author":"R Gil-Gouveia","year":"2016","unstructured":"Gil-Gouveia R, Oliveira AG, Martins IP. The impact of cognitive symptoms on migraine attack-related disability. Cephalalgia. 2016;36(5):422\u201330.","journal-title":"Cephalalgia"},{"issue":"3","key":"525_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301\u201315.","journal-title":"Cephalalgia"},{"issue":"7","key":"525_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0333102411398400","volume":"31","author":"M Lanteri-Minet","year":"2011","unstructured":"Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31(7):837\u201350.","journal-title":"Cephalalgia"},{"issue":"1","key":"525_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0333102415580099","volume":"36","author":"N Abu Bakar","year":"2016","unstructured":"Abu Bakar N, Tanprawate S, Lambru G, Torkamani M, Jahanshahi M, Matharu M. Quality of life in primary headache disorders: a review. Cephalalgia. 2016;36(1):67\u201391.","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"525_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10072-015-2188-z","volume":"36","author":"M Leonardi","year":"2015","unstructured":"Leonardi M. Burden of migraine: what should we say more? Neurol Sci. 2015;36(Suppl 1):1\u20133.","journal-title":"Neurol Sci."},{"issue":"5","key":"525_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343\u20139.","journal-title":"Neurology"},{"issue":"1","key":"525_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22\u201333.","journal-title":"J Manag Care Pharm."},{"issue":"10a","key":"525_CR14","first-page":"S54","volume":"23","author":"A Kawata","year":"2017","unstructured":"Kawata A, Shah N, Poon J, Shaffer S, Sapra S, Wilcox T, et al. G24: treatment patterns and healthcare resource use in migraine patients newly initiating a preventive treatment: interim Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINeurs using Preventive Treatment (ATTAIN) Study. J Manag Care Spec Pharm. 2017;23(10a):S54.","journal-title":"J Manag Care Spec Pharm."},{"key":"525_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3389\/fphar.2019.00363","volume":"10","author":"D Scuteri","year":"2019","unstructured":"Scuteri D, Adornetto A, Rombola L, Naturale MD, Morrone LA, Bagetta G, et al. New trends in migraine pharmacology: targeting calcitonin gene-related peptide (CGRP) with monoclonal antibodies. Front Pharmacol. 2019;10:363.","journal-title":"Front Pharmacol."},{"issue":"1","key":"525_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12883-020-01633-3","volume":"20","author":"H Deng","year":"2020","unstructured":"Deng H, Li GG, Nie H, Feng YY, Guo GY, Guo WL, et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine\u2014an updated systematic review and meta-analysis. BMC Neurol. 2020;20(1):57.","journal-title":"BMC Neurol."},{"issue":"1","key":"525_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, et al. European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.","journal-title":"J Headache Pain."},{"key":"525_CR18","doi-asserted-by":"crossref","unstructured":"Purks JL, Wilhelm EE, Shoulson I, Creveling J, Dorsey ER, Irony T, et al. Inaugural conference on incorporating patient-reported outcomes and patient preference information into clinical research, clinical care, and risk-benefit assessments for neurodegenerative diseases. Patient. 2017;10(5):541-4.","DOI":"10.1007\/s40271-017-0257-5"},{"issue":"6","key":"525_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40271-019-00396-5","volume":"12","author":"HL Benz","year":"2019","unstructured":"Benz HL, Lee TJ, Tsai JH, Bridges JFP, Eggers S, Moncur M, et al. Advancing the use of patient preference information as scientific evidence in medical product evaluation: a summary report of the patient preference workshop. Patient. 2019;12(6):553\u20137.","journal-title":"Patient."},{"issue":"1","key":"525_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40271-019-00401-x","volume":"13","author":"IL Hollin","year":"2020","unstructured":"Hollin IL, Craig BM, Coast J, Beusterien K, Vass C, DiSantostefano R, et al. Reporting formative qualitative research to support the development of quantitative preference study protocols and corresponding survey instruments: guidelines for authors and reviewers. Patient. 2020;13(1):121\u201336.","journal-title":"Patient."},{"issue":"5","key":"525_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/head.13498","volume":"59","author":"C Mansfield","year":"2019","unstructured":"Mansfield C, Gebben DJ, Sutphin J, Tepper SJ, Schwedt TJ, Sapra S, et al. Patient Preferences for preventive migraine treatments: a discrete-choice experiment. Headache. 2019;59(5):715\u201326.","journal-title":"Headache"},{"issue":"4","key":"525_CR22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1526-4610.2007.00757.x","volume":"47","author":"MF Peres","year":"2007","unstructured":"Peres MF, Silberstein S, Moreira F, Corchs F, Vieira DS, Abraham N, et al. Patients\u2019 preference for migraine preventive therapy. Headache. 2007;47(4):540\u20135.","journal-title":"Headache"},{"issue":"14","key":"525_CR23","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1177\/0333102419888222","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, et al. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia. 2019;39(14):1798\u2013808.","journal-title":"Cephalalgia"},{"issue":"6","key":"525_CR24","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/head.13534","volume":"59","author":"SD Silberstein","year":"2019","unstructured":"Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P, et al. Safety and tolerability of fremanezumab for the prevention of migraine: a pooled analysis of phases 2b and 3 clinical trials. Headache. 2019;59(6):880\u201390.","journal-title":"Headache"},{"issue":"1","key":"525_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12883-020-1609-7","volume":"20","author":"ME Bangs","year":"2020","unstructured":"Bangs ME, Kudrow D, Wang S, Oakes TM, Terwindt GM, Magis D, et al. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020;20(1):25.","journal-title":"BMC Neurol."},{"key":"525_CR26","first-page":"361","volume":"9","author":"K Callis Duffin","year":"2016","unstructured":"Callis Duffin K, Bukhalo M, Bobonich MA, Shrom D, Zhao F, Kershner JR, et al. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. Med Devices (Auckl). 2016;9:361\u20139.","journal-title":"Med Devices (Auckl)."},{"issue":"1","key":"525_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1525822X16639015","volume":"29","author":"G Guest","year":"2017","unstructured":"Guest G, Namey E, McKenna K. How many focus groups are enough? Building an evidence base for nonprobability sample sizes. Field Methods. 2017;29(1):3\u201322.","journal-title":"Field Methods"},{"key":"525_CR28","unstructured":"Serrano D, Buse DC, Reed ML, Runken MC, Lipton RB. Development of the Migraine Symptom Severity Score (MSSS): a latent variable model for migraine definition: PO-86. Headache:40. 2010;50(suppl 1):40."},{"issue":"3","key":"525_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40271-019-00407-5","volume":"13","author":"E Louis","year":"2020","unstructured":"Louis E, Ramos-Goni JM, Cuervo J, Kopylov U, Barreiro-de Acosta M, McCartney S, et al. A qualitative research for defining meaningful attributes for the treatment of inflammatory bowel disease from the patient perspective. Patient. 2020;13(3):317\u201325.","journal-title":"Patient."},{"issue":"3","key":"525_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/hec.2906","volume":"22","author":"K Obermann","year":"2013","unstructured":"Obermann K, Scheppe J, Glazinski B. More than figures? Qualitative research in health economics. Health Econ. 2013;22(3):253\u20137.","journal-title":"Health Econ."},{"issue":"3","key":"525_CR31","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/nhs.12048","volume":"15","author":"M Vaismoradi","year":"2013","unstructured":"Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398\u2013405.","journal-title":"Nurs Health Sci."},{"key":"525_CR32","volume-title":"Qualitative research & evaluation methods. Integrating theory and practice","author":"MQ Patton","year":"2015","unstructured":"Patton MQ. Qualitative research & evaluation methods. Integrating theory and practice. 4th ed. Los Angeles: SAGE Publications, Inc.; 2015.","edition":"4"},{"issue":"1","key":"525_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40271-017-0263-7","volume":"11","author":"D Ikenwilo","year":"2018","unstructured":"Ikenwilo D, Heidenreich S, Ryan M, Mankowski C, Nazir J, Watson V. The best of both worlds: an example mixed methods approach to understand men\u2019s preferences for the treatment of lower urinary tract symptoms. Patient. 2018;11(1):55\u201367.","journal-title":"Patient."},{"key":"525_CR34","unstructured":"ATLAS.ti Scientific Software Development GmbH. ATLAS.ti 7 User Guide and Reference. 2013. https:\/\/atlasti.com\/wp-content\/uploads\/2014\/05\/atlasti_v7_manual_201312.pdf?q=\/uploads\/media\/atlasti_v7_manual_201312.pdf. Accessed 26 Feb 2020."},{"issue":"3","key":"525_CR35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/160940690900800307","volume":"8","author":"J Wheeldon","year":"2009","unstructured":"Wheeldon J, Faubert J. Framing experience: concept maps, mind maps, and data collection in qualitative research. Int J Qual Methods. 2009;8(3):68\u201383.","journal-title":"Int J Qual Methods."},{"key":"525_CR36","unstructured":"Eli Lilly and Company. Emgality (galcanezumab-gnlm) injection [package insert]. U.S. Food and Drug Administration. Revised September, 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761063s000lbl.pdf. Accessed 9 Apr 2021."},{"key":"525_CR37","unstructured":"Eli Lilly Nederland B.V. Emgality (galcanezumab). Summary of product characteristics. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emgality-epar-product-information_en.pdf. Accessed 9 Apr 2021."},{"key":"525_CR38","unstructured":"Amgen Inc. Aimovig\u2122 (erenumab-aooe) injection [package insert]. U.S. Food and Drug Administration. Revised May, 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761077s000lbl.pdf. Accessed 9 Apr 2021."},{"key":"525_CR39","unstructured":"Amgen, Inc. Aimovig (erenumab-aooe) injection. Summary of product characteristics. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aimovig-epar-product-information_en.pdf. Accessed 9 Apr 2021."},{"key":"525_CR40","unstructured":"Teva Pharmaceuticals USA, Inc. AJOVY\u2122 (fremanezumab-vfrm) injection [package insert]. U.S. Food and Drug Administration. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761089s002lbl.pdf. Accessed 9 Apr 2021."},{"key":"525_CR41","unstructured":"Teva Pharmaceuticals Europe B.V. AJOVY (fremanezumab-vfrm) injection. Summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ajovy-epar-product-information_en.pdf. Accessed 9 Apr 2021."},{"issue":"6","key":"525_CR42","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1526-4610.1994.hed3406344.x","volume":"34","author":"S Kryst","year":"1994","unstructured":"Kryst S, Scherl E. A population-based survey of the social and personal impact of headache. Headache. 1994;34(6):344\u201350.","journal-title":"Headache"},{"issue":"4","key":"525_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.1468-2982.1996.1604231.x","volume":"16","author":"WF Stewart","year":"1996","unstructured":"Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia. 1996;16(4):231\u20138 (discussion 15).","journal-title":"Cephalalgia"},{"issue":"5","key":"525_CR44","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1468-2982.2008.01555.x","volume":"28","author":"S Silberstein","year":"2008","unstructured":"Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28(5):484\u201395.","journal-title":"Cephalalgia"},{"issue":"1","key":"525_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"HS American","year":"2019","unstructured":"American HS. The American headache society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1\u201318.","journal-title":"Headache"},{"issue":"5","key":"525_CR46","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38(5):815\u201332.","journal-title":"Cephalalgia"},{"issue":"2","key":"525_CR47","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11910-011-0245-4","volume":"12","author":"DD Mitsikostas","year":"2012","unstructured":"Mitsikostas DD. Nocebo in headaches: implications for clinical practice and trial design. Curr Neurol Neurosci Rep. 2012;12(2):132\u20137.","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"6","key":"525_CR48","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478\u201388.","journal-title":"Cephalalgia"},{"key":"525_CR49","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.2147\/PPA.S170636","volume":"12","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Sides R, Lanteri-Minet M, Kielbasa W, Jin Y, Selzler KJ, et al. Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. Patient Prefer Adherence. 2018;12:1785\u201395.","journal-title":"Patient Prefer Adherence."}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-021-00525-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-021-00525-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-021-00525-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T23:01:18Z","timestamp":1699138878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-021-00525-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["525"],"URL":"https:\/\/doi.org\/10.1007\/s40271-021-00525-z","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,16]]},"assertion":[{"value":"29 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Eli Lilly & Co.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jaein Seo, Charlie A. Smith, Caitlin Thomas, Tommi Tervonen, and Asha Hareendran are employees of Evidera, which was paid by Eli Lilly & Co. for work related to this study. Janet H. Ford, Virginia L. Stauffer, Robert A. Nicholson, Kevin Harrison Duffy, and Antje Tockhorn-Heidenreich are employees of Eli Lilly & Co.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Before any study procedures were initiated, the study was approved by the US central institutional review board of Ethical & Independent Review Services (Independence, MO, USA) (institutional review board reference number 19144-01). This study does not require review by a local ethics committee in the UK and Germany according to the NHS Health Research Authority and the German <i>Medicinal Products Act<\/i> (<i>Arzneimittelgesetz<\/i> \u2013AMG). The study was conducted in accordance with the International Council on Harmonization Privacy Statement, the <i>Health Insurance Portability and Accountability Act<\/i>, and the European <i>General Data Protection Regulation<\/i> and is reported in accordance with the recommendations of the COnsolidated criteria for REporting Qualitative research (COREQ) Checklist and Standards for Reporting Qualitative Research (SRQR) reporting guidelines and Good Publication Practice 3 guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided verbal and online consent to participate.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are not publicly available as no consent was sought from participants to allow sharing of data with third parties.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not Applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JS contributed to conception and planning of the work, acquisition and interpretation of the data, and drafting and critical revision of the manuscript. CAS contributed to the acquisition, analysis, and interpretation of the data and drafting the manuscript. CT contributed to the conception and planning of the work, acquisition and analysis of the data, and drafting the manuscript. TT contributed to the conception and planning of the work, interpretation of the data, and drafting the manuscript. AH contributed to the conception and planning of the work, data acquisition, and the drafting and critical revision of the manuscript. JHF contributed to the conception and planning of the work and critical revision of the manuscript. VLS contributed to the conception and planning of the work and critical revision of the manuscript. RAN contributed to the conception and planning of the work and critical revision of the manuscript. KHD contributed to the conception and planning of the work and critical revision of the manuscript. AT-H contributed to the conception and planning of the work and critical revision of the manuscript. All participated sufficiently in the work to take public responsibility for the entire content of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}